Last mentioned: 3h ago
HIMS Launches GLP-1s
Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
Settlement Reached
Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
FDA Shortage Updates
FDA begins removing specific GLP-1 dosages from the national shortage list.
Marketplace Purge
Amazon begins removing thousands of listings in the Tejocote and weight-loss categories for compliance review.
Mass Public Warning
Widespread media alerts issued to consumers across the United States regarding the 'poison' supplements.
Amazon Notification
Regulators formally notify Amazon of the presence of poisonous substances in specific marketplace listings.
Initial Detection
FDA laboratory testing identifies toxic yellow oleander in weight-loss supplements.
Settlement & Collaboration
Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.
Current Status
Regulatory bodies and industry leaders report a significant decline in animal-based IND applications.
Supply Stabilization
FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.
Litigation Surge
Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
Industry Pivot
Major pharma firms like AstraZeneca and Sanofi increase investment in human-on-a-chip technologies.
Hims & Hers GLP-1 Launch
Hims & Hers announces the launch of compounded GLP-1 injections at a significant discount to brand names.
Litigation Wave Begins
Novo Nordisk starts filing lawsuits against medical spas and pharmacies over compounded semaglutide.
FDA Modernization Act 2.0
President Biden signs legislation ending the animal testing mandate.
FD&C Act Passed
Federal Food, Drug, and Cosmetic Act mandates animal testing for all new drugs.
Federal regulators have issued an urgent public health warning regarding poisonous substances found in dietary supplements sold on Amazon's marketplace. The discovery of toxic ingredients like yellow oleander in products marketed as weight-loss aids has reignited the legal debate over marketplace liability and the adequacy of automated compliance systems.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Hims & Hers Health and Novo Nordisk have reached a settlement to end their legal dispute over compounded weight loss medications. The agreement transitions the relationship from adversarial litigation to a strategic collaboration, potentially reshaping the telehealth distribution model for GLP-1 drugs.
The pharmaceutical industry is undergoing a historic shift as the FDA Modernization Act 2.0 ends the decades-long mandate for animal testing. This transition toward New Approach Methodologies (NAMs) like organ-on-a-chip and AI modeling is redefining the legal and regulatory requirements for drug safety validation.